Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

<p>Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOX...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Carlotta Antoniotti (15352506) (author)
Otros Autores:	Alessandra Boccaccino (15352509) (author), Robert Seitz (15352512) (author), Mirella Giordano (15352515) (author), Aurélie Catteau (15352518) (author), Daniele Rossini (15086287) (author), Filippo Pietrantonio (15035729) (author), Lisa Salvatore (15352521) (author), Kimberly McGregor (15352524) (author), Francesca Bergamo (15352527) (author), Veronica Conca (15352530) (author), Simone Leonetti (15352533) (author), Federica Morano (14937009) (author), Giorgio Papiani (15352536) (author), Emiliano Tamburini (15352539) (author), Maria Bensi (15352542) (author), Sabina Murgioni (15352545) (author), Douglas Teller Ross (15352548) (author), Alessandro Passardi (15352551) (author), Isabelle Boquet (15352554) (author), Tyler J. Nielsen (15352557) (author), Jérôme Galon (15031113) (author), Matthew Gordon Varga (15352560) (author), Brock L. Schweitzer (15352563) (author), Chiara Cremolini (15352566) (author)
Publicado:	2025
Materias:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Immuno-oncology Biomarkers Gastrointestinal Cancers Colorectal cancer Immunotherapy Biomarkers for immunotherapy Translational Research Tumor Microenvironment Immune cells and the microenvironment
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Ejemplares similares